26 completed. 26 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 26 |
| Phase 2 | 4 | Completed 4 |
Follow Dysentery: new trials by email Literature Review of Dysentery trials Research Report on Dysentery
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA VENBETA6890, Placebo - Diarrhea Infectious | Phase 1 | Completed | Mark Klempner | 36 | 2025-02-11 | 2025-07-22 |
| ShigETEC Vaccine Study in Bangladesh ShigETEC live, attenuated, oral vaccine, Placebo - Healthy Volunteers | Phase 1 | Completed | Eveliqure Biotechnologies GmbH | 196 | 2023-11-26 | 2026-01-23 |
| Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122 strain CVD 1208S-122, Placebo - Shigella Infection, Enterotoxigenic Escherichia Coli Infection | Phase 1 | Completed | University of Maryland, Baltimore | 53 | 2022-09-29 | 2026-02-02 |
| Controlled Human Infection Model Challenge/Rechallenge Shigella sonnei 53G, Shigella flexneri 2a 2457T - Shigellosis | Phase 1 | Completed | PATH | 46 | 2022-04-26 | 2025-01-31 |
| A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants AltSonflex1-2-3 High Dose, AltSonflex1-2-3 Medium Dose, AltSonflex1-2-3 Low Dose - Diarrhoea | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 551 | 2021-10-06 | 2026-06-22 |
| Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults ShigETEC live, attenuated, oral vaccine, Placebo - Diarrheal Disease, Infectious, Gastrointestinal Disease | Phase 1 | Completed | Eveliqure Biotechnologies GmbH | 84 | 2020-09-16 | 2022-06-08 |
| A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants Shigella 4V, MenACWY, Rabies - Shigellosis | Phase 1 / Phase 2 | Completed | LimmaTech Biologics AG | 597 | 2019-09-02 | 2026-06-23 |
| Dose Escalating Study of Intramuscular Invaplex[AR-DETOX] Invaplex[AR-DETOX], Placebo - Diarrhea | Phase 1 | Completed | PATH | 58 | 2019-03-18 | 2021-07-29 |
| Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine - Dysentery, Dysentery, Bacillary | Phase 1 | Completed | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 180 | 2017-07-18 | 2018-10-17 |
| A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study GVGH Shigella sonnei 1790GAHB vaccine - Dysentery, Bacillary | Phase 1 | Completed | GlaxoSmithKline | 35 | 2017-03-16 | 2019-06-28 |
| Shigella WRSS1 Vaccine Trial in Bangladesh Shigella sonnei Strain WRSS1 Vaccine, Placebo - Diarrhea | Phase 1 | Completed | PATH | 16 | 2017-02-23 | 2020-03-31 |
| Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain Shigella sonnei 53G - Healthy | Phase 1 | Completed | PATH | 56 | 2016-09-12 | 2019-06-03 |
| SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers SF2a-TT15 vaccine, SF2a-TT15 vaccine + adjuvant, Placebo - Shigellosis, Bacillary Dysentery | Phase 1 | Completed | Institut Pasteur | 64 | 2016-09-01 | 2018-04-11 |
| Phase 1 Study of dmLT ID Vaccination in Healthy Adults Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine - Gastroenteritis Escherichia Coli | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 100 | 2016-06-02 | 2020-10-26 |
| Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Shigella flexneri 2a InvaplexAR - Shigellosis, Bacillary Dysentery | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 38 | 2015-10-01 | 2021-02-12 |
| Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a Flexyn2a, Placebo, Flexyn2a plus adjuvant - Shigellosis | Phase 1 | Completed | LimmaTech Biologics AG | 30 | 2015-02-01 | 2015-12-22 |
| Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults S. sonnei 1790GAHB, Placebo - Shigellosis | Phase 1 | Completed | GSK Vaccines Institute For Global Health S.r.l. | 52 | 2014-03-01 | 2016-06-21 |
| A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults. S. sonnei 1790GAHB, Placebo - Shigellosis | Phase 1 | Completed | GSK Vaccines Institute For Global Health S.r.l. | 50 | 2014-02-01 | 2019-01-23 |
| Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3 Placebo, WRSs2, WRSs3 - Shigella Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 89 | 2013-01-07 | 2019-01-28 |
| Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP CVD 1208S, a Shigella flexneri 2a live, oral vaccine, Placebo - Shigella | Phase 1 | Completed | University of Maryland, Baltimore | 26 | 2011-07-01 | 2021-04-30 |
Showing 20 of 26. Sign in to see all of them.
Dysentery, Bacillary (25) · Diarrhea (6) · Gastrointestinal Diseases (2) · Arthritis, Reactive (1) · Bacterial Infections (1) · Digestive System Diseases (1) · Enterobacteriaceae Infections (1) · Escherichia coli Infections (1) · Gastroenteritis (1) · Gram-Negative Bacterial Infections (1) · Intestinal Diseases (1)
Bacterial Infections and Mycoses (25) · Digestive System Diseases (25) · Gastroenteritis (25) · Infections (25) · Intestinal Diseases (25) · Bacterial Infections (24) · Enterobacteriaceae Infections (24) · Gastrointestinal Diseases (24) · Gram-Negative Bacterial Infections (24) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (6) · Signs and Symptoms, Digestive (6) · Arthritis (1) · Arthritis, Infectious (1)
Vaccines (4) · Adjuvants, Pharmaceutic (2) · Boostrix (1) · MenACWY (1) · Meningococcal Vaccines (1) · Shigella Vaccines (1) · Tetanus Toxoid (1) · Vi polysaccharide vaccine, typhoid (1) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (1)
PATH (5) · U.S. Army Medical Research and Development Command (4) · Eveliqure Biotechnologies GmbH (2) · GSK Vaccines Institute For Global Health S.r.l. (2) · GlaxoSmithKline (2) · LimmaTech Biologics AG (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of Maryland, Baltimore (2) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · GlycoVaxyn AG (1) · Institut Pasteur (1) · Mark Klempner (1)
United States (13) · Bangladesh (2) · France (2) · Israel (2) · Kenya (2) · Belgium (1) · China (1) · Hungary (1) · Switzerland (1) · Thailand (1) · United Kingdom (1)
Carl Mason, MD (1) · Christoph Hatz, Prof. Dr. (1) · Christopher Duplessis, MD, MPH, MS (1) · Clayton D Harro, MD, ScM (1) · David JM Lewis, MD (1) · David Tribble, MD, PhD (1) · Feng-Ying C Lin, M.D. (1) · Josphat Kosgei, MD (1) · Karen L. Kotloff, M.D. (1) · Kawsar Talaat, MD (1) · Ladaporn Bodhidatta, MD (1) · Mainga Hamaluba, MD (1)
PMID 27490698, PMID 28735965, PMID 34017343, PMID 20619378, PMID 26162850, PMID 26865592, PMID 27146000, PMID 27581434, PMID 29534721, PMID 33186516, PMID 33207794, PMID 34793505, PMID 37666695, PMID 38853614, PMID 39893179, PMID 40152601, PMID 41999631
2016 (1)